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Summary
QUESTION: Detection and treatment of infections during
pregnancy are important for both maternal and child health.
The objective of this study was to describe testing practices
and adherence to current national guidelines in Switzer-
land.
METHODS: We invited all registered practicing obstetri-
cians and gynaecologists in Switzerland to complete an an-
onymous web-based questionnaire about strategies for test-
ing for 14 infections during pregnancy. We conducted a
descriptive analysis according to demographic characterist-
ics.
RESULTS: Of 1138 invited clinicians, 537 (47.2%) re-
sponded and 520 (45.6%) were eligible as they are cur-
rently caring for pregnant women. Nearly all eligible re-
spondents tested all pregnant women for group B strep-
tococcus (98.0%), hepatitis B virus (HBV) (96.5%) and
human immunodeficiency virus (HIV) (94.7%), in accord-
ance with national guidelines. Although testing for tox-
oplasmosis is not recommended, 24.1% of respondents
tested all women and 32.9% tested at the request of the pa-
tient. Hospital doctors were more likely not to test for tox-
oplasmosis than doctors working in private practice (odds
ratio [OR] 2.52, 95% confidence interval [CI] 1.04–6.13,
p = 0.04). Only 80.4% of respondents tested all women
for syphilis. There were regional differences in testing for
some infections. The proportion of clinicians testing all
women for HIV, HBV and syphilis was lower in Eastern
Switzerland and the Zurich region (69.4% and 61.2%, re-
spectively) than in other regions (range 77.1–88.1%, p
<0.001). Most respondents (74.5%) said they would appre-
ciate national guidelines about testing for infections during
pregnancy.
CONCLUSIONS: Testing practices for infections in preg-
nant women vary widely in Switzerland. More extensive
national guidelines could improve consistency of testing
practices.
Key words: infectious diseases; pregnancy; screening;
mother to child transmission
Introduction
Untreated infections in pregnancy can cause substantial
morbidity in pregnant women and the fetus or newborn.
Transmission of infection can result from transplacental
transmission, amniotic fluid infection or during labour. Ad-
verse pregnancy outcomes include miscarriage, preterm la-
bour, premature rupture of membranes, preterm birth, still-
birth and perinatal infectious complications [1–4]. Conse-
quences for the fetus and newborn range from asymptomat-
ic infection to sepsis, fetal malformations and fetal death
[5, 6]. Several infections are acquired through sexual in-
tercourse (human immunodeficiency virus [HIV], syphilis,
chlamydia, gonorrhoea, hepatitis B virus [HBV] and herpes
simplex virus [HSV]) so there are implications for sexu-
al history taking and partner treatment. HBV, varicella and
rubella infections are preventable with vaccinations, if ad-
ministered before pregnancy. Other infections like cyto-
megalovirus (CMV), parvovirus and toxoplasmosis can be
tested for if abnormalities occur during pregnancy, but
there is no established treatment during pregnancy for these
infections.
Policies and practices for testing pregnant women for in-
fections during pregnancy differ between countries, de-
pending on the incidence and prevalence of infection, on
historical precedents, on interpretation of the research evid-
ence and on the type of health care system [7–9]. To date,
there is no European consensus on routine testing for infec-
tions during pregnancy. In Switzerland, there is no single
guideline about testing for infections in pregnancy and no
single body responsible for guidelines. The Federal Of-
fice of Public Health (FOPH) and the Swiss Society of
Gynaecology and Obstetrics (SSGO) have issued recom-
mendations for specific infections: to screen all women for
hepatitis B, HIV, group B streptococcus, varicella and ru-
bella [10–15]; further to screen pregnant women for syph-
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ilis [16], and not to screen for toxoplasmosis [17]. Testing
practices in antenatal care and adherence to national re-
commendations have not been investigated at a national
level in Switzerland. This survey was designed to describe
current practices followed by gynaecologists and obstetri-
cians in Switzerland, to identify regional differences and to
determine factors associated with testing for specific infec-
tions during antenatal care.
Methods
A multidisciplinary team of gynaecologists/obstetricians
and specialists in infectious diseases, paediatrics and public
health at University Hospital Bern, Cantonal Hospital St.
Gallen and the Institute of Social and Preventive Medicine
in Bern in Switzerland developed the survey “Testing for
infections during pregnancy in Switzerland”.
We used a web-based questionnaire created with an online
application (SurveyMonkey®). The questionnaire was
available in three languages (German, French, Italian) and
the questions were pretested by 50 gynaecologists at the
Bern University Hospital to assess readability and content
validity. A total of 12 questions were included to charac-
terise the responding doctors and their infection screening
practices. The information collected about the doctors in-
cluded the number of pregnant patients attended per year,
place of work (private practice, hospital), year of medical
board certification (specialisation) in obstetrics and gyn-
aecology, region of work in Switzerland (according to the
Swiss Federal Statistics Office [18]: Eastern Switzerland,
Zürich region, Central Switzerland, North-western
Switzerland, Midland region [Bern, Solothurn, Neuchâtel,
Jura and Fribourg], Lake Geneva region [Geneva, Vaud and
Valais] and Ticino) and gender of the physician. In addi-
tion, we asked whether doctors took a sexual history from
pregnant women at increased risk of sexually transmitted
infection (STI), defined as having more than one partner
and unprotected vaginal intercourse with different partners
during pregnancy. Clinicians were then instructed to indic-
ate the strategy they applied, based on their clinical prac-
tice, for testing for each of the following infections (in
alphabetical order): bacterial vaginosis (BV), Chlamydia
trachomatis (chlamydia), cytomegalovirus (CMV), gonor-
rhoea, hepatitis B virus (HBV), human Immunodeficiency
virus (HIV), herpes simplex virus (HSV), hepatitis C virus
(HCV), parvovirus B19, rubella, group B streptococcus
(GBS), syphilis, toxoplasmosis and varicella zoster virus
(VZV). There were five mutually exclusive categories of
testing strategy: universal screening, testing women at high
risk (multiple sex partners, a history of injecting drug use
or any other risk judged relevant to the infection), testing if
the pregnant woman had clinical symptoms or if there were
fetal signs (e.g. on ultrasound), testing at the request of the
women, and not testing at all.
The initial survey invitation was distributed to all clinicians
who are active members of the SSGO, which covers 98%
of all practicing obstetricians and gynaecologists in
Switzerland. The invitation e-mail contained a short de-
scription of the survey as well as the web link for the online
survey. Two reminders were sent out over a total time peri-
od of 5 months between February and June 2015. This
study was exempt from approval of the ethics committee,
as it did not include patients’ data but collected anonym-
ous information about the views and practices of healthcare
professionals only.
Statistical analyses were conducted using STATA 12 (Stata
Corporation, College Station, TX). We described the fre-
quency of testing strategies for each infection as percent-
ages, excluding missing values. We considered region of
work as the main exposure variable and analysed overall
differences between regions with chi-square tests. Three
outcomes were analysed with logistic regression models:
testing according to recommendation (i.e. testing all wo-
men for HIV, HBV and syphilis), not testing for toxoplas-
mosis, and inquiring about a sexual history. For each out-
come, we examined univariable associations with region of
work, workplace (hospital or private practice), years since
specialisation and gender. Results are expressed as odds ra-
tios (OR) and 95% confidence intervals (95% CI). For test-
ing according to recommendation a multivariable model of
the association between region of work and testing prac-
tice, controlling for workplace, years since specialisation
and gender. We present the probability of testing in each
region (with 95% CI), after controlling for potential con-
founding. We present results about screening practices in
two groups: infections that are mentioned in guidelines and
infections that are not mentioned.
Results
Characteristics of participants
A total of 1138 clinicians were sent an email invitation
and 537 (47.2%) responded. Seventeen of 537 (3.2%) the
responding doctors were not seeing pregnant patients and
thus did not answer further questions. The characteristics
of the 520 eligible participating doctors are shown in table
1. The distributions of eligible participants according to sex
and region of work did not differ from those of all members
of the SSGO (see appendix, supplementary table S3).
Sexual history taking
Only 94/515 (18.3%) of the respondents reported that they
took a sexual history from all their patients during antenatal
care and 31.7% never did so (table 1). Overall, 137 (26.6
%) asked only single women about their sexual risks and
98 (19.0%) asked only at the beginning of pregnancy. Male
doctors were more likely to ask about sexual history and
sexual risk (26.4%) than female doctors (16.1%; OR 1.87,
95% CI 1.19–2.96, p = 0.007) during antenatal care. The
evaluation of sexual history was not associated with region
of work, years since specialization or place of work (sup-
plementary table S1).
Infections mentioned in guidelines
We found that nearly all respondents reported that they
tested all women for GBS (98.0%, 502/512), HBV (96.5%,
497/515) and HIV (94.7%, 479/506) during antenatal care,
in accordance with national recommendations (fig. 1).
Amongst these infections, the time at which testing was
done varied most for HBV with 55.5% (287/517) reporting
testing during the first trimester, 7.5% (39/517) in the
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second and 31.3% (162 /517) routinely in the third tri-
mester.
Syphilis testing for all pregnant women was reported by
80.4% (410/510) of respondents and 10.6% (54/510) said
that they tested women at high risk of infection; only 4.7%
(24/510) reported that they never test for syphilis during
pregnancy. There were geographic differences in the pro-
portion of clinicians that tested all women for syphilis
(table 2, fig. 2); more than 90% of physicians in most re-
Figure 1
Testing practice for each infection, percentage of respondents
reporting each practice.
None = no testing for this infection; symptoms = test only women
with symptoms; risk = test only women with specific risk factors;
demand = test women who request it; all = test all women for this
infection
BV = bacterial vaginosis; CMV = cytomegalovirus; GBS = group B
streptococcus; GO = gonorrhoea; HBV = hepatitis B virus; HCV =
hepatitis C virus; HIV = human immunodeficiency virus; HSV,
herpes simplex virus
Figure 2
Percentage of participants reporting testing all pregnant women for
the indicated disease, by region.
BV = bacterial vaginosis; CMV = cytomegalovirus; GBS = group B
streptococcus; GO = gonorrhoea; HBV = hepatitis B virus; HCV =
hepatitis C virus; HIV = human immunodeficiency virus; HSV =
herpes simplex virus.
gions (96.6% in the Geneva region and 92.0% in North-
western Switzerland) but only 65.4% in the Zurich region
and 73.3% in Eastern Switzerland (p <0.001). In these
regions 10.4% and 7.9%, respectively, reported that they
tested only women at high risk of syphilis. For women
with positive syphilis serology test results, 45.1% (227/
503) doctors reported that they send their patients to infec-
tious disease specialists for antibiotic treatment.
When we focused on doctors who reported that they tested
all pregnant women for HIV, HBV and syphilis, there were
no differences according to place of work (hospital or
private practice), year of specialisation or sex of the parti-
cipant compared with doctors who did not test all women.
There was a difference between regions, with lower rates of
reported testing in Eastern Switzerland and Zurich region
(69.4% and 61.2%, respectively) compared with the other
regions (range 77.1–88.1%, p <0.001). This difference re-
mained after adjusting for doctor’s gender, place of work
and year of specialist certification (fig. 3, supplementary
table S2).
The majority (447/510, 87.6%) of respondents reported
testing women for rubella and 51.5% (259/503) for vari-
cella immunity, with no geographical variation.
For toxoplasmosis, 24.1% (117/486) of all respondents re-
ported testing all women, 32.9% (160/486) tested at the
request of the pregnant woman and 24.1% (117/486) did
not test any women. Doctors in the Geneva region reported
testing 47.4% (27/57) of all women and those in Eastern
Switzerland only 10.5% (8/75, p across region <0.001)
(table 2). Hospital doctors were more likely than doctors
working in private practice not to test for toxoplasmosis
(OR 2.52, 95% CI 1.04–6.13, p = 0.04), but there was no
association with gender or year of specialisation.
Infections not mentioned in guidelines
For genital tract infections, 65.0% (333/512) respondents
reported testing all women for BV, 49.7% (252/507) for
chlamydia and 18.3% (91/498) for gonorrhoea. There were
geographical differences in testing for all three infections.
In general, doctors in German-speaking regions and the Ti-
cino reported testing all women for these infections more
often than doctors in the French-speaking region. Doctors
practicing in hospitals were more likely than those in
Figure 3
Probability of reporting testing of all women for human
immunodeficiency virus (HIV), hepatitis B virus (HBV) and syphilis,
by region adjusted for place of work, year of specialist certification,
and gender. The dashed line indicates the overall mean, boxes are
the point estimate, bars are 95% confidence intervals (CIs).
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private practice to report testing all women for chlamydia
(52/67, 77.6% and 145/352 41.2%, respectively) and go-
norrhoea (27/65, 41.5% and 44/346, 12.7%, respectively; p
<0.001 for both comparisons).
Overall, 32.7% (161/493) of respondents reported testing
all pregnant women and 13.2% (65/493) reported testing
women at high risk of CMV (fig. 1). Testing practices for
CMV were geographically heterogeneous (table 2, fig. 2):
80.7% of respondents in the Geneva region, compared with
50% or fewer of respondents in all other regions reported
testing all women for CMV (p <0.001).
For hepatitis C, 40.0% (197/492) of respondents reported
testing all women and another 41.5% (204/492) reported
testing women at high risk (e.g. women with a history of
injection drug use). The doctors most likely to report test-
ing all pregnant women for hepatitis C during pregnancy
were found in the Geneva region (34/56, 60.7%) and Cent-
ral Switzerland (25/46, 54.3%), compared with 18.6% (13/
70) in Eastern Switzerland (p across all regions <0.001).
Only 18.0% (81/520) respondents reported that they had,
according to their opinion, enough information to decide
about testing strategies and 388 (74.5%) of all responding
clinicians mentioned that they would appreciate clearer
guidelines about testing for infections during pregnancy in
the future.
Discussion
This is the first national study in Switzerland to have as-
sessed obstetricians’ and gynaecologists’ testing practices
for 14 infections during pregnancy. More than 90% of re-
spondents reported that they tested all women for HIV,
HBV and GBS and 88% for rubella, in accordance with na-
tional recommendations. Overall, 80% of respondents re-
ported testing all women for syphilis. We found that 24%
of respondents reported testing all women for toxoplasmos-
is, 7 years after the publication of recommendations not to
screen. Our study demonstrated geographical variations in
testing strategies for several infections. Most respondents
said that they would like to have national guidelines on
testing for infections in pregnancy.
The strength of this study was the large sample of practi-
cing obstetricians and gynaecologists in Switzerland. The
participation rate was 47% and respondents were repres-
entative of all SSGO members according to sex and region
of work. Limitations of the survey include the potential
for participation bias. If respondents are more likely to be
those who test for infections, we will have overestimated
the coverage of antenatal screening for infections. Reported
levels of testing do not necessarily correspond to testing of
individual women in practice. These levels of testing might
Table 1: Characteristics of participating doctors.
Number of participants 520
Gender (male) n = 517, 171 (33%)
Number of pregnancies managed (>100) n = 519, 218 (42%)
Workplace n = 519,
Private practice 363 (70%)
Cantonal hospital 67 (13%)
Regional hospital 54 (10%)
University hospital 24 (5%)
Others 11 (2%)
Year of specialist training n = 517
1986–1995 163 (32%)
1996–2005 166 (32%)
2006–2015 118 (23%)
In progress 39 (8%)
No specialist training 31 (6%)
Region n = 519,
Middle lands 111 (21%)
North-west 78 (15%)
East 76 (15%)
Geneva 59% (11%)
Ticino 8 (2%)
Central 51 (10%)
Zurich 136 (26%)
Sexual history inquired n = 515,
Yes 94 (18%)
No 163 (32%)
Only single women 137 (27%)
Only start of pregnancy 98 (19%)
Other 23 (4%)
Availability of information n = 511,
Guidelines would be helpful 381 (75%)
Not enough information but can search
for it
38 (7%)
I have enough information 92 (18%)
Table 2: Number and percentage of participants testing all pregnant women by region.
Middle lands
(n = 111)
North-west
(n = 78)
East
(n = 76)
Geneva
(n = 59)
Ticino
(n = 8)
Central
(n = 51)
Zurich
(n = 136)
All pregnant women tested for: Number (percentage) of participants p value
Bacterial vaginosis 53 (48%) 57 (73%) 59 (78%) 15 (27%) 7 (88%) 32 (64%) 110 (82%) <0.001
Group B streptococcus 110 (100%) 75 (97%) 74 (99%) 55 (96%) 8 (100%) 51 (100%) 129 (96%) 0.36
Chlamydia 31 (28%) 43 (56%) 45 (59%) 12 (22%) 5 (71%) 27 (55%) 88 (66%) <0.001
Cytomegalovirus 45 (42%) 11 (15%) 20 (28%) 46 (81%) 4 (50%) 13 (29%) 22 (17%) <0.001
Gonorrhoea 13 (12%) 20 (26%) 13 (17%) 3 (6%) 4 (57%) 11 (24%) 27 (21%) 0.003
Hepatitis B virus 105 (95%) 77 (99%) 74 (99%) 54 (92%) 8 (100%) 49 (96%) 129 (97%) 0.30
Hepatitis C virus 38 (36%) 33 (43%) 13 (19%) 34 (61%) 6 (75%) 25 (54%) 48 (37%) <0.001
Human immunodeficiency virus 106 (97%) 68 (89%) 66 (92%) 59 (100%) 8 (100%) 49 (100%) 122 (92%) 0.024
Herpes simplex virus 2 (2%) 2 (3%) 3 (4%) 3 (6%) 2 (25%) 3 (7%) 3 (2%) 0.039
Parvovirus 20 (20%) 7 (10%) 13 (18%) 10 (19%) 1 (14%) 7 (16%) 12 (9%) 0.28
Rubella 95 (88%) 69 (91%) 65 (86%) 55 (93%) 6 (75%) 42 (86%) 114 (86%) 0.61
Syphilis 94 (85%) 69 (92%) 55 (73%) 57 (97%) 7 (88%) 40 (82%) 87 (65%) <0.001
Toxoplasmosis 22 (22%) 12 (16%) 8 (11%) 27 (47%) 3 (38%) 19 (44%) 26 (20%) <0.001
Varicella 47 (44%) 39 (51%) 46 (61%) 23 (42%) 6 (75%) 25 (51%) 72 (55%) 0.12
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also be overestimated if respondents felt that they were ex-
pected to say that they tested. The anonymous nature of the
survey should have reduced such a bias.
Adherence to national recommendations for universal
screening in pregnancy
We found very high adherence to specific recommenda-
tions published on the SSGO website stating that all preg-
nant women should be tested for GBS [11], HBV [10] and
HIV [11]. Studies in Switzerland have shown successful
prevention of mother to child transmission of GBS by in-
trapartum antibiotics in women with GBS colonisation [19]
and very low levels of early onset sepsis with GBS in new-
borns (0.12/1000 live births) [20]. Testing for GBS is al-
most universal practice in Switzerland according to our
survey results. This might be explained by a clear Swiss re-
commendation for GBS screening in pregnant women and
is an example of effective implementation of a national
screening strategy that was introduced by the SSGO.
International recommendations for universal
screening: global campaign to eliminate congenital
syphilis
Our results show that antenatal syphilis screening could
be improved in Switzerland. There are large geographical
variations, which might suggest that doctors in some re-
gions screen all women but others only test women at high
risk of syphilis. The World Health Organization (WHO)
aims to eliminate mother to child transmission of syphilis
and recommends screening of all pregnant women to allow
timely diagnosis and treatment of infected women and their
partners [21]. The number of infectious syphilis cases in
pregnant women in Switzerland increased between 2006
and 2009 [16]. Furthermore, the United States Centers for
Disease Control and Prevention reported an increase in
cases of congenital syphilis in 2014 [22]. This finding un-
derlines the importance of screening all women for syphilis
during pregnancy.
Screening for rubella and varicella and opportunities
for vaccination
We found 88% of Swiss obstetricians and gynaecologists
test all pregnant women for rubella antibodies, as recom-
mended by the SFOPH. Serological testing might reflect
the fact that many women do not have their immunisation
records. According to a serological study of women who
gave birth, rates of seronegative status for rubella were as
low as 3.2% in Swiss/German/Austrian women [23] com-
pared with 7.8% of patients from other European countries.
Even with low seronegative rates, the postpartum period
gives an important opportunity to vaccinate seronegative
women for rubella and varicella in order to provide protec-
tion in subsequent pregnancies.
Withdrawen recommendations for screening:
toxoplasmosis
In 2009, Swiss recommendations about screening for tox-
oplasmosis changed and stated that routine screening for
toxoplasmosis in pregnancy should not be done [17]. In-
stead, hygienic measures (e.g. avoiding consumption of
raw meat) are recommended for all pregnant women. The
main reasons for this decision were the low prevalence of
toxoplasmosis in Switzerland, the limited options for ther-
apy following seroconversion during pregnancy, and the
low specificity of toxoplasmosis serology testing resulting
in many false positive tests. False positive test results lead
to unnecessary anxiety and might even result in termina-
tion of pregnancy of a unaffected fetus. Our survey results
indicate that nearly a quarter of clinicians still test all preg-
nant women for toxoplasmosis, and one third are still test-
ing at the request of the patient. Neighbouring countries,
especially France, still recommend screening for toxoplas-
mosis during pregnancy [24]. Accordingly, the highest pro-
portion of doctors testing for toxoplasmosis was found in
the French-speaking part of Switzerland (48%). These find-
ings show the difficulty of changing practice after a shift in
screening recommendations.
Controversies about screening for infections in
pregnancy: bacterial vaginosis and chlamydia
Heterogeneity in testing practices for infections in preg-
nancy can reflect ongoing debates about the effectiveness
of screening. Testing rates for BV in asymptomatic preg-
nant women varied geographically, from a quarter in the
Geneva region to more than 80% in the Zurich region. Al-
though the correlation between BV and severe complica-
tions in pregnancy and postpartum (preterm birth, late mis-
carriage, postpartum endometritis) is well established, the
benefits of treatment of BV in pregnancy have been de-
bated because of inconsistent study results [25]. Neverthe-
less, if BV is treated early in pregnancy (before 16 weeks),
the risk for preterm birth might be reduced [26, 27]. Fur-
thermore, the prevalence of BV in Switzerland has been
shown to be as high as 32% [28]. Similarly, observational
studies show associations between chlamydia infection in
pregnancy [2, 4] but the lack of randomised controlled tri-
als [29] perpetuates debate about whether routine screening
of asymptomatic pregnant women reduces these outcomes
[30]. Screening of all pregnant women for chlamydia is re-
commended in countries such as the USA [31], Estonia,
Germany and Latvia, but other countries such as the UK
actively recommend not screening, based on an evidence
review [30].
History taking for sexual risk and sexually transmitted
infections
Adverse outcomes of STIs such as chlamydia, gonorrhoea,
syphilis, HBV, HIV and HSV in pregnancy are well doc-
umented [1–4]. For example, the risk of HIV transmission
to the newborn is highest in women with incident HIV in-
fection during pregnancy [32]. Numbers of reported cases
of syphilis, chlamydia and gonorrhoea are increasing in
Switzerland [33]. Acquisition of these infections is associ-
ated with the number of current and past sexual partners,
with non-use of condoms and with the behaviours of sexual
partners [34]. Sexual history taking is a sensitive topic, es-
pecially in pregnant women as they often attend consulta-
tions together with their male partner, so assessing risk in
regard to STI is challenging [35]. This survey shows a need
to improve sexual history taking during pregnancy, espe-
cially since levels of sexual risk assessment were low, irre-
spective of the time since specialist certification.
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New evidence from research: perinatal treatment for
HCV and HBV
Hepatitis C screening is carried out by 40% of our survey
respondents. Until now, there have been no measures to re-
duce transmission risk of HCV (about 6%) to the newborn
during pregnancy and delivery [36]. New directly acting
antivirals, which are able to clear HCV infection in more
than 90% within 10–12 weeks of therapy, should stimu-
late a re-evaluation of testing and treatment strategies be-
fore and during pregnancy [37]. Treatment of the mother
in the pregnancy interval or before conception could avoid
any HCV exposure of newborns of subsequent pregnancies
[38]. A recent UK study suggests that general HCV screen-
ing during pregnancy could be cost effective [39].
Timely HBV screening during pregnancy has important
implications for prevention of mother to child transmission.
Nearly all doctors in our survey routinely test for HBV
(96.5%), which is recommended by the Swiss national
health authorities and the SSGO. Treatment of HBV-infec-
ted pregnant women with high viral load reduces mother
to child transmission in both actively and passively vaccin-
ated newborns [40]. Therefore, women positive for HBV
surface antigen should be assessed for viral load and
offered treatment during the third trimester of gestation.
This is not yet included in the Swiss national guidelines,
which were last published in 2007 and should be updated.
Conclusion
Our survey reached nearly half of all registered obstet-
ricians and gynaecologists in Switzerland and found that
three quarters would appreciate clear guidelines about test-
ing for infections during pregnancy. National guidelines for
HIV, HBV and GBS testing show that wide dissemination
and clear recommendations allow high and consistent im-
plementation.
We conclude that measures should be taken to provide a
consistent format for recommendations for all relevant in-
fections in pregnancy. Such recommendations should be
evidence-based, straightforward and transparent, as well
as practice- and patient-oriented, in order to achieve high
adherence by doctors. As an additional benefit, a more
uniform national strategy with high adherence will allow
regular evaluation of the current national epidemiological
situation of infections in pregnant women. The results of
this survey can be used by healthcare authorities to make
decisions about the evaluation and implementation of
antenatal infection screening programmes in Switzerland.
More extensive national guidelines could improve consist-
ency of testing practices.
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Appendix: Heterogeneity in testing practices for infections during pregnancy:
national survey across Switzerland
Table S1: Univariable logistic regression models for testing for HIV, HBV and syphilis, not testing for toxoplasmosis and taking a sexual history, according to region, clinic
characteristic, year of specialist training and gender..
Testing for HIV, HBV and syphilis Not testing for toxoplasmosis Sexual history taking
Odds ratio (95% CI) and p value
Region
Zurich 1 (reference) 1 (reference) 1 (reference)
Middle lands 2.82 (1.54–5.13) <0.001 0.82 (0.44–1.53) 0.54 0.79 (0.39–1.57) 0.49
North-west 3.62 (1.74–7.54) <0.001 1.21 (0.64–2.31) 0.56 0.77 (0.35–1.66) 0.50
East 1.44 (0.78–2.66) 0.25 1.50 (0.80–2.80) 0.20 1.19 (0.58–2.43) 0.64
Geneva 4.70 (1.98–11.17) <0.001 0.42 (0.17–1.02) 0.06 1.38 (0.64–2.95) 0.41
Central 2.13 (1.00–4.55) 0.05 0.69 (0.29–1.63) 0.39 1.32 (0.59–2.93) 0.50
Ticino 4.43 (0.53–37.10) 0.17 1.00 (0.19–5.20) 1.00 4.67 (1.09–19.98) 0.038
Clinic characteristic
Private practice 1 (reference) 1 (reference) 1 (reference)
Cantonal hospital 1.10 (0.59–2.06) 0.77 1.27 (0.68–2.37) 0.46 0.47 (0.21–1.08) 0.08
Regional hospital 1.12 (0.56–2.23) 0.75 1.93 (1.03–3.61) 0.040 0.70 (0.31–1.54) 0.37
University Hospital 1.72 (0.57–5.16) 0.34 2.52 (1.04–6.13) 0.041 1.11 (0.40–3.09) 0.84
Others 2.75 (0.34–22.28) 0.34 0.40 (0.05–3.25) 0.39 0.89 (0.19–4.20) 0.88
Year of specialist training
1986–1995 1 (reference) 1 (reference) 1 (reference)
1996–2005 0.93 (0.55–1.55) 0.77 0.60 (0.35–1.03) 0.06 0.73 (0.42–1.27) 0.27
2006–2015 1.31 (0.73–2.38) 0.37 0.84 (0.48–1.48) 0.55 0.62 (0.33–1.17) 0.14
Still In training 0.87 (0.39–1.96) 0.74 0.98 (0.42–2.26) 0.96 0.41 (0.14–1.24) 0.11
No specialist training 0.59 (0.25–1.38) 0.22 1.76 (0.76–4.06) 0.19 1.80 (0.77–4.20) 0.17
Gender
Female 1 (reference) 1 (reference) 1 (reference)
Male 0.73 (0.48–1.12) 0.15 1.40 (0.90–2.16) 0.13 1.87 (1.19–2.96) 0.007
CI = confidence interval; HBV = hepatitis B virus; HIV = human immunodeficiency virus
Table S2: Multivariable logistic regression for testing for HIV, HBV and syphilis according to region, clinic characteristics, year of specialist training and gender.
Odds ratio (95% CI) p-value
Region
Zurich 1 (reference)
Middle lands 2.82 (1.52–5.24) 0.001
North-west 3.57 (1.69–7.57) <0.001
East 1.43 (0.74–2.76) 0.29
Geneva 4.46 (1.84–10.78) <0.001
Ticino 3.92 (0.46–33.16) 0.21
Central 2.39 (1.10–5.20) 0.028
Workplace
Private practice 1 (reference)
Cantonal hospital 1.05 (0.49–2.24) 0.90
Regional hospital 1.38 (0.64–2.97) 0.41
University Hospital 2.31 (0.54–9.85) 0.26
Others 2.65 (0.25–28.19) 0.42
Year of specialist training
1986–1995 1 (reference)
1996–2005 0.95 (0.55–1.65) 0.86
2006–2015 1.25 (0.65–2.41) 0.50
Still in training 0.64 (0.22–1.86) 0.41
No specialist training 0.62 (0.25–1.56) 0.31
Gender
Female 1 (reference)
Male 0.64 (0.39–1.04) 0.07
CI = confidence interval; HBV = hepatitis B virus; HIV = human immunodeficiency virus
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Table S3: Characteristics of the members of the Swiss Society of Gynaecology and Obstetrics.
1. Place of work
Region Cantons
Lake Geneva region Geneva, Vaud, Valais 18.7%
Midland region Berne, Fribourg, Jura, Neuchâtel, Solothurn 18%
North-western Switzerland Aargau, Basel-Landschaft, Basel-Stadt 12.6%
Zurich Zurich 24.8%
Eastern Switzerland Appenzell Ausserrhoden, Appenzell Innerrhoden, Glarus, Graubunden, St-Gallen,
Schaffhausen, Thurgau
11.1%
Central Switzerland Luzern, Nidwalden, Obwalden, Schwyz, Uri, Zug 8.4%
Ticino Ticino 3%
Other Foreign (German/Austrian/French) 3.4%
2. Percentage male and female
– 63% women
– 37% men
3. Mean age
Mean age 47 years
NB: For date of birth, information given by members is incomplete.
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Figures (large format)
Figure 1
Testing practice for each infection, percentage of respondents reporting each practice.
None = no testing for this infection; symptoms = test only women with symptoms; risk = test only women with specific risk factors; demand = test
women who request it; all = test all women for this infection
BV = bacterial vaginosis; CMV = cytomegalovirus; GBS = group B streptococcus; GO = gonorrhoea; HBV = hepatitis B virus; HCV = hepatitis C
virus; HIV = human immunodeficiency virus; HSV, herpes simplex virus
Original article Swiss Med Wkly. 2016;146:w14325
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 10 of 12
Figure 2
Percentage of participants reporting testing all pregnant women for the indicated disease, by region.
BV = bacterial vaginosis; CMV = cytomegalovirus; GBS = group B streptococcus; GO = gonorrhoea; HBV = hepatitis B virus; HCV = hepatitis C
virus; HIV = human immunodeficiency virus; HSV = herpes simplex virus.
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Figure 3
Probability of reporting testing of all women for human immunodeficiency virus (HIV), hepatitis B virus (HBV) and syphilis, by region adjusted for
place of work, year of specialist certification, and gender. The dashed line indicates the overall mean, boxes are the point estimate, bars are
95% confidence intervals (CIs).
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